EUCTR2013-000719-26-GB进行中（未招募）1 期
A single centre, double blind, non-inferiority study to evaluate the antidepressant activity of Viotra™ compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who have an unsatisfactory response / are resistant to SSRIs. - Viotra™ in MDD
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent.
- •2. Male or female.
- •3. Age 18-65 years inclusive.
- •4. Subjects with a current episode of moderate to severe Major Depressive Disorder meeting the criteria of DSM IV -TR and documented using the brief structured interview Mini International Neuropsychiatric Interview (MINI) version 5.0 and with a minimum duration of two weeks and a maximum of twelve months.
- •5. Minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screening and =12 at the end of the lead-in phase prior to randomisation.
- •6. Female subjects of childbearing potential must have a negative pregnancy test at the Screening Visit and must use an acceptable method of contraception throughout the study and for 30 days after. The following contraceptive methods are acceptable: hormonal (e.g. oral, injection, transdermal patch, implant, cervical ring), barrier (e.g. condom or diaphragm with spermicidal agent), intrauterine system (IUS) or intrauterine device (IUD). If hormonal contraceptives are used by female subjects they must be established for 6 weeks before the first administration of test product. Male sterilisation is considered an acceptable form of contraception if the appropriate post-vasectomy documentation (absence of sperm) is provided. Sexual abstinence is considered acceptable if this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. To be considered „not of child-bearing potential female subjects must be surgically sterilized or post-menopausal (defined as no menses for one year or an FSH value >40 IU/L). Male subjects with female partners of child-bearing potential must use an acceptable method of contraception throughout the study and for 30 days after.
- •7. Able to understand and comply with the requirements of the study as judged by the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Considered by the investigator to be at significant risk of suicide or scoring 5 or more on the Montgomery Asberg Depression Rating Scale (c) question 10.
- •2. Significant other psychiatric illness which would interfere with trial assessments – co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis.
- •3. Significant physical illness which would interfere with trial assessments.
- •4. Recent (within 1 week of screening) antidepressants (except for fluoxetine [within 4 weeks of screening] and St John’s Wort or MAOI’s [within 14 days of screening]).
- •5. Benzodiazepine or any other psychotropic medication including lithium or other mood stabilisers within 1 week of screening. Propranolol is permitted where a stable dose (minimum 30 days) has been prescribed for non-psychotropic reasons e.g. high blood pressure.
- •6. Oral anticoagulant therapy within one month of screening.
- •7. Formal psychotherapy or alternative treatments for one week prior to screening or during the study defined as that administered by a specialist healthcare professional, using formal structured techniques.
- •8. Reduced hepatic function defined as liver enzyme levels =2.5 times upper limit of normal.
- •9. Renal insufficiency defined as creatinine clearance <30 mL/min.
- •10. Epilepsy – Patients with epilepsy or those susceptible to seizures should not be included. Where it has not been possible to exclude an underlying susceptibility greater than that of the general study patient population with sufficient confidence and/or an old condition cannot be regarded as resolved, then the patient should not be included.
- •11. Uncontrolled Hypothyroidism.
- •12. Uncontrolled Hypertension.
- •13. Acute porphyria.
- •14. Urinary retention, prostatic hypertrophy, narrow angle glaucoma or increased intraocular pressure or any other clinically relevant contraindication stated in the SMPCs for citalopram, tramadol or amitriptyline (See Appendix 5).
- •15. History of significant cardiac dysrhythmia or history of myocardial infarction within 1 year prior to screening.
- •16. Significant history of alcohol or substance abuse.
- •17. Regular alcohol intake above the recommended UK guideline of 4 units per day for males or 3 units per day for females.
- •18. Pregnant or lactating women.
- •19. Known hepatitis B or C or human immunodeficiency virus (HIV) or syphilis seropositivity. Note: testing for hepatitis, syphilis or HIV will not be performed as part of the screening procedures.
- •20. A corrected QT interval of >470ms for female subjects of >450ms for male subjects, calculated using the QTcB correction formula, or second degree or higher heart block on an ECG recording, at screening.
- •21. Allergy to the study drugs or excipients.
- •22. Treatment with another investigational medicinal product within the 30 days prior to screening.
研究者
相似试验
已完成
不适用
SB-773812 administered in adults with schizophreniaPER-066-05GLAXOSMITHKLINE PERU S.A.,
已完成
2 期
The safety and efficacy of Cpn10 in psoriasisACTRN12606000040561CBio Limited24
尚未招募
4 期
A comparative study with an objective to evaluate the efficacy and safety of a Single-pill combination of Cilnidipine 10 mg and Telmisartan 40 mg compared with Telmisartan 40 mg to explore the effects of the treatments on BP management and Renal outcomes in 200 Indian Diabetic hypertensive patientsCTRI/2022/03/041486JB Chemicals and Pharmaceuticals Ltd
进行中（未招募）
不适用
A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid TherapyTreatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid TherapyMedDRA version: 8.1Level: LLTClassification code 10058019Term: Cancer painEUCTR2006-003493-97-FRArchimedes Development Ltd.200
尚未招募
3 期
A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid TherapyBreak Through Cancer Pain10027656NL-OMON31160I3Research25